Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 127

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 127
---
 businesses, we have no current understandings, agreements or commitments to do so. 69 MARKET PRICE AND DIVIDEND INFORMATION Market Price Our Common Stock and Public Warrants are listed on Nasdaq under the symbols “CERO” and “CEROW,” respectively. The closing price of our Common Stock and our Public Warrants as reported on Nasdaq on February 3, 2025 was $2.00 per share and $0.014 per warrant. Holders As of February 3, 2025, there were 133 holders of record of our Common Stock and 32 holders of record of our Public Warrants. The numbers of holders of record do not include for example a substantially greater number of “street name” holders or beneficial holders whose securities are held of record by banks, brokers and other financial institutions. Dividend Policy We have not paid any cash dividends to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment of any cash dividends will be within the discretion of our Board at such time. 70 CAPITALIZATION The following table sets forth our cash and our capitalization as of September 30, 2024, on:

| ● | an            
 actual basis; |

| ● | on                                                                                            
 an as adjusted basis giving effect to (i) the exercise of 2,462 Preferred Warrants for 2,462  
 shares of Series A Preferred Stock and the receipt of the cash proceeds of such exercises,    
 (ii) the conversion of 3,484 shares of Series A Preferred Stock into 759,369 shares of Common 
 Stock, including the shares of Series A Preferred Stock set forth in clause (i), (iii) the    
 conversion of 213 shares of Series B Preferred Stock into 41,376 shares of Common Stock,      
 (iv) the issuance of 247,914 warrants to purchase shares of Common Stock and (v) the issuance 
 of 436,384 shares of Common Stock pursuant to the Keystone Equity Financing, in each case     
 from October 1, 2024 through January 8, 2025; and                                             |

| ● | on a pro forma basis, giving effect to the adjustments                                                                                
 in the preceding bullet and the issuance and sale of 4,000,000 shares of Common Stock in this offering at the assumed public offering 
 price of $2.00 per share, which is the last reported sale price of our Common Stock on